Buy Low, Dispense High
The pharmaceutical industry is approaching a singularity. Between 2025 and 2030, a wave of patent expirations—often described as the “super-cliff”—will […]
Buy Low, Dispense High Read Post »
Forecast Pharma Revenue Without the Cliff Myth
The foundational error in pharmaceutical valuation lies in conflating the statutory patent term with commercial exclusivity. Generalist investors and market
Forecast Pharma Revenue Without the Cliff Myth Read Post »
Steal Years Back From Your Patent Cliff
Big pharma used to treat loss of exclusivity as a weather event. You saw the date on the Gantt chart,
Steal Years Back From Your Patent Cliff Read Post »
Secure the Future of Branded Generics
The business model for off-patent medicine is undergoing a forced evolution. For four decades, the Hatch-Waxman Act provided a predictable
Secure the Future of Branded Generics Read Post »
Sell Trust, Not Molecules: The 100% Premium Strategy
The pharmaceutical sector operates on a punishing mathematical divide. In 2024, generic and biosimilar medicines filled 90% of all prescriptions
Sell Trust, Not Molecules: The 100% Premium Strategy Read Post »
Where Patent Law Draws the Line for Compounded Medications: A Strategic Analysis of Regulatory Exemptions, Intellectual Property Rights, and Market Realities
The Convergence of Federal Exclusivity and Public Health Necessity The pharmaceutical industry operates on a fundamental tension between two opposing
Sell More After Patents Die
Reclaiming Revenue in the Patent Cliff The pharmaceutical industry faces a contraction of unprecedented scale. Between 2025 and 2030, nearly
Sell More After Patents Die Read Post »
Predict the Cliff
Pharmaceutical revenue is a melting ice cube. Between 2025 and 2030, the global industry faces a wave of patent expirations
Win the Biosimilar War
The pharmaceutical industry is currently moving through the most concentrated period of exclusivity loss in its history. Between 2025 and
Win the Biosimilar War Read Post »
